Drug Landscape ›
Phosphate Binder ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 13
Most-reported reactions
Nausea — 3 reports (23.08%) Abdominal Pain — 2 reports (15.38%) Application Site Pain — 1 report (7.69%) Arthritis — 1 report (7.69%) Azotaemia — 1 report (7.69%) Blood Phosphorus Increased — 1 report (7.69%) Blood Potassium Increased — 1 report (7.69%) Blood Thyroid Stimulating Hormone Increased — 1 report (7.69%) Cardiac Disorder — 1 report (7.69%) Cardiac Failure Acute — 1 report (7.69%)
Source database →
Phosphate Binder in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Phosphate Binder approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Phosphate Binder in United States?
Assiut University is the originator. The local marketing authorisation holder may differ — check the official source linked above.